[go: up one dir, main page]

MA45543B1 - Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations - Google Patents

Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations

Info

Publication number
MA45543B1
MA45543B1 MA45543A MA45543A MA45543B1 MA 45543 B1 MA45543 B1 MA 45543B1 MA 45543 A MA45543 A MA 45543A MA 45543 A MA45543 A MA 45543A MA 45543 B1 MA45543 B1 MA 45543B1
Authority
MA
Morocco
Prior art keywords
beta
n3pglu
amyloid peptide
antibodies
n3pglu antibodies
Prior art date
Application number
MA45543A
Other languages
English (en)
Other versions
MA45543A (fr
Inventor
Ronald Bradley Demattos
Michael Carl Irizarry
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA45543A publication Critical patent/MA45543A/fr
Publication of MA45543B1 publication Critical patent/MA45543B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un traitement par induction à court terme avec des anticorps anti-n3pglu aß d'une maladie caractérisée par le dépôt de aß dans la tête, qui inclus la maladie d'alzheimer (ad), le syndrome de down et l'angiopathie amyloïde cérébrale (caa). Dans certains modes d'emploi, une dose d'induction de 10 à 60 mg/kg d'un anticorps anti-n3pglu aß est administrée à des patients pendant une période inférieure ou égale à 6 mois.
MA45543A 2016-07-01 2017-06-23 Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations MA45543B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662357579P 2016-07-01 2016-07-01
PCT/US2017/038999 WO2018005282A1 (fr) 2016-07-01 2017-06-23 Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées

Publications (2)

Publication Number Publication Date
MA45543A MA45543A (fr) 2019-05-08
MA45543B1 true MA45543B1 (fr) 2023-08-31

Family

ID=59295341

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45543A MA45543B1 (fr) 2016-07-01 2017-06-23 Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations

Country Status (29)

Country Link
US (2) US11312763B2 (fr)
EP (2) EP4272828A3 (fr)
JP (4) JP7165588B2 (fr)
KR (3) KR20230021773A (fr)
CN (3) CN109415433A (fr)
AU (1) AU2017291414B2 (fr)
BR (1) BR112018073843A2 (fr)
CA (1) CA3029550C (fr)
DK (1) DK3478712T5 (fr)
EA (1) EA201892690A1 (fr)
ES (1) ES2958508T3 (fr)
FI (1) FI3478712T3 (fr)
HR (1) HRP20230861T1 (fr)
HU (1) HUE062980T2 (fr)
IL (1) IL263788B2 (fr)
LT (1) LT3478712T (fr)
MA (1) MA45543B1 (fr)
MD (1) MD3478712T2 (fr)
MX (2) MX2018016066A (fr)
NZ (1) NZ772768A (fr)
PL (1) PL3478712T3 (fr)
PT (1) PT3478712T (fr)
RS (1) RS64386B1 (fr)
SG (1) SG11201810371XA (fr)
SI (1) SI3478712T1 (fr)
TW (2) TWI798751B (fr)
UA (2) UA127101C2 (fr)
WO (1) WO2018005282A1 (fr)
ZA (1) ZA201807633B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
EP3521308B1 (fr) * 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Anticorps humanisés et dé-immunisés
WO2019169448A1 (fr) * 2018-03-09 2019-09-12 St Vincent's Institute Of Medical Research Anticorps multi-spécifiques
WO2020023530A2 (fr) * 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Méthodes de traitement et de prévention de la maladie d'alzheimer
CN111184725B (zh) * 2020-02-27 2020-12-01 慈溪市人民医院医疗健康集团(慈溪市人民医院) 一种防治脑梗塞的药物制剂及其制备方法
TWI843040B (zh) * 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (fr) 2021-05-24 2022-12-01 Eli Lilly And Company Anticorps anti-amyloïde bêta et leurs utilisations
CN118475610A (zh) 2021-10-29 2024-08-09 伊莱利利公司 靶向白细胞介素-34的化合物和方法
MX2024005146A (es) * 2021-10-29 2024-05-13 Lilly Co Eli Compuestos y metodos dirigidos a interleucina-34.
WO2023146818A2 (fr) * 2022-01-26 2023-08-03 T3D Therapeutics, Inc. Procédés de traitement de troubles cérébraux liés à l'amyloïde à l'aide de nouveaux composés et d'anticorps
EP4472679A1 (fr) * 2022-02-03 2024-12-11 Eli Lilly and Company Imagerie de tau régionale pour le diagnostic et le traitement de la maladie d'alzheimer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1397539A (en) * 1920-01-14 1921-11-22 Odell Risdon Moore Egg-carton
ES2184660T5 (es) 2000-02-24 2013-05-09 Washington University St. Louis Anticuerpos humanizados que secuestran el péptido amiloide beta
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1911765A3 (fr) 2002-07-24 2008-04-23 Innogenetics N.V. Prévention, traitement et diagnostic des maladies associées à la formation et/ou agrégation bêta-amyloïde
CA2538220A1 (fr) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Utilisation d'un anticorps
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
JO2824B1 (en) 2005-12-12 2014-09-15 اف . هوفمان لاروش ايه جي Antibody glycosylate in the changing region
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
EP2468770B1 (fr) 2006-07-14 2017-12-20 AC Immune S.A. Anticorps humanisés contre beta amyloide.
UA95996C2 (ru) 2007-01-18 2011-09-26 Эли Лилли Энд Компани Пегилированный fab-фрагмент антитела, который специфически связывается с бета-амилоидным пептидом
SI2182983T1 (sl) * 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
KR20110036809A (ko) 2008-06-12 2011-04-11 아피리스 아게 파킨슨병과 관련된 증상을 치료하기 위한 화합물
CA2730073A1 (fr) 2008-07-09 2010-01-14 University Of Zurich Procede d'activation de la neurogenese
US8058405B2 (en) 2008-07-21 2011-11-15 Probiodrug (AG) Antibodies specific for N-terminal truncated and pyroglutamate modified amyloid-beta peptides
CN101397539B (zh) * 2008-10-14 2011-10-05 中国人民解放军第三军医大学 组织工程组织仿生培养的模拟人体生理应力的施力装置
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011151076A2 (fr) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Anticorps monoclonaux ciblant des oligomères aβ
ES2564252T3 (es) * 2010-08-12 2016-03-21 Eli Lilly And Company Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
WO2012021475A2 (fr) 2010-08-12 2012-02-16 Eli Lilly And Company ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
EP2928494A4 (fr) 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh Procédé de réduction des plaques amyloïdes cérébrales au moyen d'anticorps anti-ass
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
SG11201606490YA (en) 2014-02-08 2016-09-29 Genentech Inc Methods of treating alzheimer's disease
WO2015175769A1 (fr) * 2014-05-15 2015-11-19 Biogen Ma Inc. Procédés de détection d'oligomères bêta-amyloïdes dans des échantillons biologiques
WO2015191825A1 (fr) * 2014-06-13 2015-12-17 Biogen Ma Inc. Méthodes pour la détection et la mesure de la protéine beta amyloïde dans des échantillons biologiques
JP6201928B2 (ja) * 2014-08-04 2017-09-27 トヨタ自動車株式会社 車両制御装置
TWI570127B (zh) 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
WO2016053767A1 (fr) 2014-09-30 2016-04-07 Merck Sharp & Dohme Corp. Nouvelles formes cristallines d'un inhibiteur de bace, compositions, et utilisation associées
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途

Also Published As

Publication number Publication date
AU2017291414B2 (en) 2019-11-21
EA201892690A1 (ru) 2019-05-31
WO2018005282A1 (fr) 2018-01-04
TWI735600B (zh) 2021-08-11
CA3029550A1 (fr) 2018-01-04
DK3478712T5 (da) 2024-09-09
RS64386B1 (sr) 2023-08-31
TWI798751B (zh) 2023-04-11
NZ772768A (en) 2024-11-29
IL263788A (en) 2019-01-31
ZA201807633B (en) 2021-05-26
IL263788B1 (en) 2024-06-01
JP2021059546A (ja) 2021-04-15
EP3478712B1 (fr) 2023-07-19
MX2023001299A (es) 2023-02-22
UA129392C2 (uk) 2025-04-09
JP2021059547A (ja) 2021-04-15
MD3478712T2 (ro) 2024-01-31
JP7241058B2 (ja) 2023-03-16
CN114917338A (zh) 2022-08-19
TW202140544A (zh) 2021-11-01
US20220235122A1 (en) 2022-07-28
JP2023123503A (ja) 2023-09-05
SI3478712T1 (sl) 2023-10-30
US20190382471A1 (en) 2019-12-19
HUE062980T2 (hu) 2023-12-28
JP7165588B2 (ja) 2022-11-04
TW201811363A (zh) 2018-04-01
NZ748496A (en) 2021-02-26
KR20190012208A (ko) 2019-02-08
FI3478712T3 (fi) 2023-10-02
CN114887054A (zh) 2022-08-12
UA127101C2 (uk) 2023-04-19
EP4272828A3 (fr) 2024-01-10
BR112018073843A2 (pt) 2019-02-26
MA45543A (fr) 2019-05-08
PT3478712T (pt) 2023-08-21
AU2017291414A1 (en) 2018-12-13
SG11201810371XA (en) 2018-12-28
CA3029550C (fr) 2023-08-22
JP2019518783A (ja) 2019-07-04
CN109415433A (zh) 2019-03-01
KR20230021773A (ko) 2023-02-14
LT3478712T (lt) 2023-08-25
EP3478712A1 (fr) 2019-05-08
KR20210024213A (ko) 2021-03-04
KR102221402B1 (ko) 2021-03-02
PL3478712T3 (pl) 2023-11-06
EP4272828A2 (fr) 2023-11-08
MX2018016066A (es) 2019-04-24
DK3478712T3 (da) 2023-09-04
ES2958508T3 (es) 2024-02-09
US11312763B2 (en) 2022-04-26
IL263788B2 (en) 2024-10-01
HRP20230861T1 (hr) 2023-11-10

Similar Documents

Publication Publication Date Title
MA45543B1 (fr) Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
EA201891286A1 (ru) АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
EA201892286A1 (ru) Лекарственные формы с модифицированным высвобождением для снижения злоупотреблений
MX2017005875A (es) Metodos para tratar enfermedades oculares.
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
EA201791138A1 (ru) Фармацевтическая композиция, ее приготовление и применения
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA45202B1 (fr) Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
MA39957A (fr) Vaccin néonatal
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
CO2020001742A2 (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil
MX2019003720A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
EA201992284A1 (ru) Композиции и способы лечения синуклеинопатий
EA202092756A1 (ru) Конденсированные бициклические соединения для применения в качестве ингибиторов убиквитин-специфической пептидазы 30
MA49557B1 (fr) Formulations à action prolongée